GR940300095T1 - Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient. - Google Patents

Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient.

Info

Publication number
GR940300095T1
GR940300095T1 GR940300095T GR940300095T GR940300095T1 GR 940300095 T1 GR940300095 T1 GR 940300095T1 GR 940300095 T GR940300095 T GR 940300095T GR 940300095 T GR940300095 T GR 940300095T GR 940300095 T1 GR940300095 T1 GR 940300095T1
Authority
GR
Greece
Prior art keywords
dichloromethylenedephosphonic
tablet
acid
active ingredient
improved bioavailability
Prior art date
Application number
GR940300095T
Other languages
English (en)
Inventor
Walter Preis
Bernd Muesel
Guenter Dr Neugebauer
Rolf-Dieter Dr Gabel
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25927331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR940300095(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE9307393U external-priority patent/DE9307393U1/de
Priority claimed from DE19934322057 external-priority patent/DE4322057A1/de
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of GR940300095T1 publication Critical patent/GR940300095T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR940300095T 1993-05-15 1995-01-31 Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient. GR940300095T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE9307393U DE9307393U1 (de) 1993-05-15 1993-05-15 Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
DE19934322057 DE4322057A1 (de) 1993-07-02 1993-07-02 Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff

Publications (1)

Publication Number Publication Date
GR940300095T1 true GR940300095T1 (en) 1995-01-31

Family

ID=25927331

Family Applications (2)

Application Number Title Priority Date Filing Date
GR940300095T GR940300095T1 (en) 1993-05-15 1995-01-31 Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient.
GR950402574T GR3017547T3 (en) 1993-05-15 1995-09-28 Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GR950402574T GR3017547T3 (en) 1993-05-15 1995-09-28 Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient.

Country Status (25)

Country Link
US (1) US5650168A (el)
EP (2) EP0697890A1 (el)
JP (1) JP3699110B2 (el)
KR (1) KR100263284B1 (el)
CN (1) CN1041797C (el)
AT (2) ATE128363T1 (el)
AU (1) AU687744B2 (el)
BR (1) BR9307859A (el)
CA (1) CA2162470C (el)
CZ (1) CZ287984B6 (el)
DE (1) DE59300688D1 (el)
DK (1) DK0625355T5 (el)
ES (1) ES2065313T5 (el)
FI (1) FI111519B (el)
GR (2) GR940300095T1 (el)
HU (1) HU220872B1 (el)
IL (1) IL106743A (el)
NO (1) NO307548B1 (el)
NZ (1) NZ254765A (el)
PL (1) PL173026B1 (el)
RU (1) RU2134103C1 (el)
SK (1) SK281193B6 (el)
TW (1) TW350772B (el)
UA (1) UA39884C2 (el)
WO (1) WO1994026310A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94926C (fi) 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
CZ289261B6 (cs) * 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
US8163306B2 (en) * 2003-09-19 2012-04-24 Sun Pharma Advanced Research Company Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
CN100370972C (zh) * 2006-01-10 2008-02-27 北京申科联华科技有限公司 一种具有益气养阴、活血复脉功效的片剂及制备方法
CA2694638A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813121A1 (de) * 1977-03-29 1978-10-12 Procter & Gamble Verwendung von dichlormethan-diphosphonatverbindungen bei der bekaempfung von collagen-erkrankungen und zur wundheilung
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
DE3804686A1 (de) * 1988-02-15 1989-08-24 Henkel Kgaa Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
FI83421C (fi) † 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Also Published As

Publication number Publication date
IL106743A0 (en) 1993-12-08
FI945313A (fi) 1994-12-13
NO307548B1 (no) 2000-04-25
PL173026B1 (pl) 1998-01-30
JPH08509697A (ja) 1996-10-15
HUT70214A (en) 1995-09-28
GR3017547T3 (en) 1995-12-31
SK4895A3 (en) 1997-01-08
CZ287984B6 (cs) 2001-03-14
JP3699110B2 (ja) 2005-09-28
DK0625355T4 (da) 2003-10-06
AU4702093A (en) 1994-12-12
CA2162470C (en) 1998-06-16
KR100263284B1 (ko) 2000-08-01
FI945313A0 (fi) 1994-11-11
ES2065313T1 (es) 1995-02-16
HU9403160D0 (en) 1995-02-28
EP0625355A1 (de) 1994-11-23
KR960702322A (ko) 1996-04-27
IL106743A (en) 1999-11-30
CA2162470A1 (en) 1994-11-24
ES2065313T3 (es) 1995-12-01
CN1041797C (zh) 1999-01-27
HU220872B1 (en) 2002-06-29
NO944405D0 (no) 1994-11-17
AU687744B2 (en) 1998-03-05
PL307133A1 (en) 1995-05-02
RU2134103C1 (ru) 1999-08-10
ES2065313T5 (es) 2004-01-01
EP0697890A1 (de) 1996-02-28
WO1994026310A1 (de) 1994-11-24
CZ10095A3 (en) 1995-10-18
BR9307859A (pt) 1996-01-09
FI111519B (fi) 2003-08-15
NZ254765A (en) 1997-02-24
SK281193B6 (sk) 2001-01-18
NO944405L (no) 1994-11-24
ATE128363T1 (de) 1995-10-15
CN1095267A (zh) 1994-11-23
EP0625355B2 (de) 2003-06-25
UA39884C2 (uk) 2001-07-16
EP0625355B1 (de) 1995-09-27
DK0625355T5 (da) 2003-12-01
US5650168A (en) 1997-07-22
AT128U1 (de) 1995-03-27
DK0625355T3 (da) 1995-12-27
TW350772B (en) 1999-01-21
DE59300688D1 (de) 1995-11-02

Similar Documents

Publication Publication Date Title
EP0645136A3 (en) Pharmaceutical preparation of the type: physiologically active substance with sustained release.
PH30982A (en) Optically active 5H-pyrrolo Ä3,4-bÜ pyrazine derivative, its preparation and pharmaceutical compositions containing it.
GR3036937T3 (en) Pharmaceutical formulations.
GR3036164T3 (en) Formulations containing hyaluronic acid.
HK1034645A1 (en) Fungicidal active compound combinations.
ZA926019B (en) Pharmaceutical spheroid formulation.
EP0671911A4 (en) CARBOXY-PEPTIDYL DERIVATIVES FOR USE AS ACTIVE ANTI-DEGENERATIVE AGENTS.
GR940300095T1 (en) Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient.
EP0645391A3 (en) Aminobenzoic acid derivatives.
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
EG20417A (en) Dihalopropene compounds insecticide acaricide containing same as active ingredient
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
ZA927499B (en) Cyclic-substituted imidazolyl-propenoic acid derivatives.
AU7546591A (en) 1-azabicyclic compounds, processes and pharmaceutical compositons containing them
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
ZA927501B (en) Imidazolyl-propenoic acid derivatives.
EP0638951A3 (en) Lead acid battery.
ZA929330B (en) Thiazolyl-substituted quinolylmethoxyphenylacetic acid derivatives.
EP0586812A3 (en) Medicines containing glicentin as an active ingredient.
PL327584A1 (en) Active substance quckly releasing tablet containing tolphenamica acid or its pharmaceutically acceptable salt
ZA927506B (en) New drug formulation.
EP0618222A3 (en) Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid.
ZA928275B (en) Quinoxaline-carboxylic and -phosphonic acid derivatives.
EP0583606A3 (en) New cardioactive hydrazono-5-beta, 14-beta-androstanes, process for their preparation and the pharmaceutical compositions containing them.